Q2 EPS Forecast for Avalo Therapeutics Raised by Analyst

Avalo Therapeutics, Inc. (NASDAQ:AVTX) – Equities research analysts at Wedbush lifted their Q2 2025 earnings per share (EPS) estimates for shares of Avalo Therapeutics in a research report issued on Thursday, March 20th. Wedbush analyst R. Driscoll now expects that the company will earn ($1.25) per share for the quarter, up from their prior estimate of ($1.40). Wedbush currently has a “Outperform” rating and a $18.00 target price on the stock. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($19.07) per share. Wedbush also issued estimates for Avalo Therapeutics’ Q3 2025 earnings at ($1.31) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($0.94) EPS, Q1 2026 earnings at ($0.79) EPS, Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.86) EPS, Q4 2026 earnings at ($0.66) EPS and FY2026 earnings at ($1.40) EPS.

Several other equities research analysts have also commented on AVTX. BTIG Research began coverage on shares of Avalo Therapeutics in a report on Thursday, December 19th. They issued a “buy” rating and a $40.00 price target for the company. HC Wainwright reissued a “neutral” rating on shares of Avalo Therapeutics in a report on Thursday, March 20th. Jefferies Financial Group assumed coverage on Avalo Therapeutics in a report on Tuesday. They set a “buy” rating and a $23.00 target price for the company. Stifel Nicolaus began coverage on Avalo Therapeutics in a research report on Tuesday. They set a “buy” rating and a $36.00 target price on the stock. Finally, Piper Sandler initiated coverage on Avalo Therapeutics in a research report on Friday, February 28th. They issued an “overweight” rating and a $48.00 price target for the company. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $33.00.

Avalo Therapeutics Stock Performance

AVTX stock opened at $8.54 on Monday. Avalo Therapeutics has a 1-year low of $4.60 and a 1-year high of $34.46. The business has a 50-day moving average price of $7.51 and a 200 day moving average price of $9.14.

Institutional Investors Weigh In On Avalo Therapeutics

Several institutional investors have recently bought and sold shares of the company. RA Capital Management L.P. purchased a new stake in shares of Avalo Therapeutics during the 3rd quarter valued at $9,186,000. Ikarian Capital LLC grew its stake in Avalo Therapeutics by 1,673.0% during the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock worth $9,218,000 after buying an additional 915,629 shares during the last quarter. Affinity Asset Advisors LLC increased its position in Avalo Therapeutics by 1,123.9% during the 4th quarter. Affinity Asset Advisors LLC now owns 550,765 shares of the company’s stock valued at $4,092,000 after buying an additional 505,765 shares in the last quarter. Velan Capital Investment Management LP purchased a new stake in Avalo Therapeutics in the fourth quarter valued at about $817,000. Finally, Geode Capital Management LLC boosted its holdings in Avalo Therapeutics by 937.0% in the fourth quarter. Geode Capital Management LLC now owns 104,853 shares of the company’s stock worth $779,000 after acquiring an additional 94,742 shares in the last quarter. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.